Skip to main content
profile image
Selected Works of John M. Pagel, MD, PhD
Article
Phase I trial of {alpha}-particle therapy with actinium-225 (225Ac)-lintuzumab (anti-CD33) and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML.
Journal of Clinical Oncology (2015)
  • Joseph G. Jurcic, Columbia University
  • Farhad Ravandi, University of Texas MD Anderson Cancer Center
  • John M. Pagel, Cancer Institute
  • Jae Hong Park
  • B. Douglas Smith, Johns Hopkins University School of Medicine
  • Dan Douer, Roswell Park Cancer Institute
  • Moshe Yair Levy, Baylor University
  • Elihu Estey, Fred Hutchinson Cancer Research Center
  • Hagop M. Kantarjian, University of Texas Health Science Center at Houston
  • Dennis Earle
  • Dragan Cicic
  • David A. Scheinberg, Memorial Sloan Kettering Cancer Center
Link
Disciplines
Publication Date
May 20, 2015
Citation Information
Joseph G. Jurcic, Farhad Ravandi, John M. Pagel, Jae Hong Park, et al.. "Phase I trial of {alpha}-particle therapy with actinium-225 (225Ac)-lintuzumab (anti-CD33) and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML." Journal of Clinical Oncology Vol. 33 (2015) p. 7050
Available at: http://works.bepress.com/john-pagel/58/